Using our MS-based immunopeptidomics approach (24, 68–70), we were able to identify naturally presented HLA class I and II neoepitopes derived from mutated NPM1 and IDH2 in primary AML samples. The gene discussed is NPM1; the disease is acute myeloid leukemia.